Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial (Breast Cancer Research and Treatment, (2017), 165, 2, (329-341), 10.1007/s10549-017-4304-7);Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial

Breast Cancer Research and Treatment

Volumn 165, Issue 2, 2017, Pages 329-341

  Cortés, Javier ^a   Rugo, Hope S ^b   Awada, Ahmad ^c   Twelves, Chris ^d   Perez, Edith A ^e   Im, Seock–ah ^f   Gómez Pardo, Patricia ^g   Schwartzberg, Lee S ^h   Diéras, Veronique ⁱ   Yardley, Denise A ^j   Potter, David A ^k   Mailliez, Audrey ^l   Moreno Aspitia, Alvaro ^a   Ahn, Jin Seok ^m   Zhao, Carol ⁿ   Hoch, Ute ⁿ   Tagliaferri, Mary ⁿ   Hannah, Alison L ^o   O’Shaughnessy, Joyce ^p  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JULES BORDET INSTITUTE   (Belgium)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e MAYO CLINIC   (United States)

^f Seoul National University Hospital   (South Korea)

^g VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^h WEST CLINIC   (United States)

ⁱ INSTITUT CURIE   (France)

^j SARAH CANNON RESEARCH INSTITUTE   (United States)

^k UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^l CENTRE OSCAR LAMBRET   (France)

^m Sungkyunkwan University School of Medicine   (South Korea)

ⁿ NEKTAR THERAPEUTICS   (United States)

^o Texas Oncology Baylor Charles A Sammons Cancer Center/US Oncology ^*  (United States)

^p BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Brain metastases; Chemotherapy; Etirinotecan pegol; Metastatic breast cancer; NKTR 102

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; ERIBULIN; ETIRINOTECAN PEGOL; GEMCITABINE; IXABEPILONE; PACLITAXEL; VINORELBINE TARTRATE;

ADULT; AGED; ANEMIA; ARTICLE; ASCITES; BRAIN METASTASIS; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EXPLORATORY RESEARCH; FEMALE; FOLLOW UP; HUMAN; HYPOKALEMIA; HYPONATREMIA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MEDICAL HISTORY; METASTATIC BREAST CANCER; MORTALITY RISK; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT HISTORY OF RADIOTHERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SURVIVAL RATE; VOMITING;

EID: 85020739938     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-017-4482-3     Document Type: Erratum

References (48)

1. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271–3277. doi:10.1200/JCO.2009.25.9820
2. Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22:3608–3617. doi:10.1200/JCO.2004.01.175
3. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A; International Breast Cancer Study Group (IBCSG) (2006) Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 17(6):935–944. doi:10.1093/annonc/mdl064
4. Lin NU, Winer EP (2007) Brain metastases: the HER2 paradigm. Clin Cancer Res 13(6):1648–1655. doi:10.1158/1078-0432.CCR-06-2478
5. Lombardi G, Di Stefano AL, Farina P, Zagonel V, Tabouret E (2014) Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature. Cancer Treat Rev 40(8):951–959. doi:10.1016/j.ctrv.2014.05.007
6. Soni A, Ren Z, Hameed O, Chanda D, Morgan CJ, Siegal GP, Wei S (2015) Breast cancer subtypes predispose the site of distant metastases. Am J Clin Pathol 143(4):471–478. doi:10.1309/AJCPYO5FSV3UPEXS
7. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423
8. Kodack DP, Askoxylakis V, Ferraro G, Fukumura D, Jain R (2015) Emerging strategies for treating brain metastases from breast cancer. Cancer Cell 27(2):163–175. doi:10.1016/j.ccell.2015.01.001
9. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP (2008) Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113:2638–2645. doi:10.1002/cncr.23930
10. Melisko ME, Moore DH, Sneed PK, De Franco J, Rugo HS (2008) Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival. J Neurooncol 88:359–365. doi:10.1007/s11060-008-9578-5
11. Lin NU (2013) Breast cancer brain metastases: new directions in systemic therapy. Ecancermedicalscience 7:307. doi:10.3332/ecancer.2013.307
12. Hambrecht A, Jandial R, Neman J (2011) Emerging role of brain metastases in the prognosis of breast cancer patients. Breast Cancer (Dove Med Press) 3:79–91. doi:10.2147/BCTT.S19967
13. Lim E, Lin NU (2012) New insights and emerging therapies for breast cancer brain metastases. Oncology (Williston Park) 26(652–659):663
14. Arslan C, Dizdar O, Altundaq K (2014) Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update. Expert Opin Pharmacother 15(12):1558–1643. doi:10.1517/14656566.2014.929664
15. Lim E, Lin NU (2014) Updates on the management of breast cancer brain metastases. Oncology (Williston Park) 28(7):572–578
16. Gabathuler R (2010) Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 37(1):48–57. doi:10.1016/j.nbd.2009.07.028
17. Gil-Gil MJ, Martinez-Garcia M, Sierra A, Conesa G, Del Barco S, González-Jimenez S, Villà S (2014) Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline. Clin Transl Oncol 16:436–446. doi:10.1007/s12094-013-1110-5
18. Dawood S, Broglio K, Esteva FJ, Yang W, Kau SW, Islam R, Albarracin C, Yu TK, Green M, Hortobagyi GN, Gonzalez-Angulo AM (2009) Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 20(4):621–627. doi:10.1093/annonc/mdn682
19. Niwińska A, Murawska M, Pogoda K (2010) Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 21:942–948. doi:10.1093/annonc/mdp407
20. Morris PG, Murphy CG, Mallam D, Accordino M, Patil S, Howard J, Omuro A, Beal K, Seidman AD, Hudis CA, Fornier MN (2012) Limited overall survival in patients with brain metastases from triple negative breast cancer. Breast J 18(4):345–350. doi:10.1111/j.1524-4741.2012.01246.x
21. Hoch U, Staschen C-M, Johnson R, Eldon MA (2014) Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother Pharmacol 74(6):1125–1137. doi:10.1007/s00280-014-2577-7
22. Adkins CE, Nounou MI, Hye T, Mohammad AS, Terrell-Hall T, Mohan NK, Eldon MA, Hoch U, Lockman PR (2015) NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer. BMC Cancer 15:685. doi:10.1186/s12885-015-1672-4
23. th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 6-10, 2016 (P1-12-05)
24. Perez EA, Awada A, O’Shaughnessy J, Rugo HS, Twelves C, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Cortes J (2015) Etirinotecan pegol (NKTR-102) versus treatment of physician’s choice in anthracyline- taxane- and capecitabine-treated advanced breast cancer. Lancet Oncol 16(15):1556–1568. doi:10.1016/S1470-2045(15)00332-0
25. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30(4):419–425. doi:10.1200/JCO.2011.38.0527
26. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M (2012) Effect of tumor subtype on survival and the graded prognostic assessment (GPA) for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys 82(5):2111–2117. doi:10.1016/j.ijrobp.2011.02.027
27. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. doi:10.1016/j.ejca.2008.10.026
28. Witzel I, Oliveira-Ferrer L, Pantel K, Müller V, Wikman H (2016) Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Res 18(1):8. doi:10.1186/s13058-015-0665-1
29. Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW (2008) Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 112(11):2359–2367. doi:10.1002/cncr.23468
30. Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, Camidge DR, Chang SM, Dancey J, de Vries EG, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wen PY; Response Assessment in Neuro-Oncology (RANO) group (2015) Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 16(6):e270–e278. doi:10.1016/S1470-2045(15)70057-4
31. Fokstuen T, Wilking N, Rutqvist LE, Wolke J, Liedberg A, Signomklao T, Fernberg JO (2000) Radiation therapy in the management of brain metastases from breast cancer. Breast Cancer Res Treat 62:211–216. doi:10.1023/A:1006486423827
32. Saito EY, Viani GA, Ferrigno R, Nakamura RA, Novaes PE, Pellizzon CA, Fogaroli RC, Conte M (2006) Whole brain radiation therapy in management of brain metastasis: results and prognostic factors. Radiat Oncol 1:20. doi:10.1186/1748-717X-1-20
33. Viani GA, Castilho MS, Salvajoli JA, Pellizzon AC, Novaes PE, Guimarães FS, Conte MA, Fogaroli RC (2007) Whole brain radiotherapy for brain metastases from breast cancer: estimation of survival using two stratification systems. BMC Cancer 7:153. doi:10.1186/1471-2407-7-53
34. Nagpal S, Recht CK, Bertrand S, Thomas RP, Ajlan A, Pena J, Gershon M, Coffey G, Kunz PL, Li G, Recht LD (2015) Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma. J Neurooncol 123(2):277–282. doi:10.1007/s11060-015-1795-0
35. Robins HI, Zhang P, Gilbert MR, Chakravarti A, de Groot JF, Grimm SA, Wang F, Lieberman FS, Krauze A, Trotti AM, Mohile N, Kee AY, Colman H, Cavaliere R, Kesari S, Chmura SJ, Mehta M (2016) A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. J Neurooncol 126(2):309–316. doi:10.1007/s11060-015-1966-z
36. Chamberlain MC, Grimm S, Phuphanich S, Recht L, Zhu JZ, Kim L, Rosenfeld S, Fadul CE; Brain Tumor Investigational Consortium (2014) A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the Brain Tumor Investigational Consortium (BTIC). J Neurooncol 118(2):335–343. doi:10.1007/s11060-014-1437-y
37. Jaeckle K, Schiff D, Anderson SK, Galanis E, Stella PJ, Flynn PJ, Sarkaria JN, Giannini C, Erickson BJ, Buckner JC (2013) NCCTG (Alliance) N0572: a phase II trial of sorafenib and temsirolimus in recurrent glioblastoma patients who progress following prior RT/temozolomide and VEGF inhibitors. J Clin Oncol 31(suppl) (abstract 2014)
38. Norden AD, Schiff D, Ahluwalia MS, Lesser GJ, Nayak L, Lee EQ, Rinne ML, Muzikansky A, Dietrich J, Purow B, Doherty LM, LaFrankie DC, Pulverenti JR, Rifenburg JA, Ruland SF, Smith KH, Gaffey SC, McCluskey C, Ligon KL, Reardon DA, Wen PY (2015) Phase II trial of triple-receptor tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. J Neurooncol 121(2):297–302. doi:10.1007/s11060-014-1631-y
39. Han SJ, Rolston JD, Molinaro AM, Clarke JL, Prados MD, Chang SM, Berger MS, DeSilva A, Butowski NA (2014) Phase II trial of 7 days on/7 days off temozolomide for recurrent high-grade glioma. Neuro Oncol 16(9):1255–1262. doi:10.1093/neuonc/nou044
40. Muhic A, Poulsen HS, Sorensen M, Grunnet K, Lassen U (2013) Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme. J Neurooncol 111(2):205–212. doi:10.1007/s11060-012-1009-y
41. Kreisl TN, Smith P, Sul J, Salgado C, Iwamoto FM, Shih JH, Fine HA (2013) Continuous daily sunitinib for recurrent glioblastoma. J Neurooncol 111(1):41–48. doi:10.1007/s11060-012-0988-z
42. Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I (2013) Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol 15(2):242–250. doi:10.1093/neuonc/nos295
43. Friday BB, Anderson SK, Buckner J, Yu C, Giannini C, Geoffroy F, Schwerkoske J, Mazurczak M, Gross H, Pajon E, Jaeckle K, Galanis E (2012) Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol 14(2):215–221. doi:10.1093/neuonc/nor198
44. Chamberlain MC, Johnston SK (2011) Salvage therapy with single agent bendamustine for recurrent glioblastoma. J Neurooncol 05(3):523–530. doi:10.1007/s11060-011-0612-7
45. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Friedman AH, Herndon JE 2nd, Marcello J, Norfleet JA, McLendon RE, Sampson JH, Friedman HS (2011) Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 101(1):57–66. doi:10.1007/s11060-010-0217-6
46. Wen PY, Schiff D, Cloughesy TF, Raizer JJ, Laterra J, Smitt M, Wolf M, Oliner KS, Anderson A, Zhu M, Loh E, Reardon DA (2011) A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol 13(4):437–446. doi:10.1093/neuonc/noq198
47. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Friedman AH, Herndon JE 2nd, Marcello J, Norfleet JA, McLendon RE, Sampson JH, Friedman HS (2010) Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol 96(2):219–230. doi:10.1007/s11060-009-9950-0
48. Cortés J, Rugo HS, Twelves C, Awada A, Perez EA, Im SA, Zhao C, Hoch U, Tomkinson D, Buchanan J, Tagliaferri M, Hannah A, O’Shaughnessy J (2016) Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial. Springerplus 5(1):1033. doi:10.1186/s40064-016-2446-4